The landscape of antidepressant treatment has shifted dramatically in recent years, with several new medications receiving FDA approval that work faster and through entirely different brain pathways than the SSRIs and SNRIs that dominated prescribing for decades. Among the most notable is Auvelity, approved in August 2022 as the first oral rapid-acting antidepressant, with clinical labeling showing statistically significant efficacy versus placebo starting at just one week — a stark contrast to the four-to-six-week waiting period that has long frustrated patients and clinicians alike. For the millions of older adults living with major depressive disorder, including those navigating early cognitive decline or caring for a loved one with dementia, faster relief is not a luxury but a medical necessity. These approvals matter beyond psychiatry.
Depression is both a risk factor for dementia and a common companion to it, affecting up to 40 percent of people with Alzheimer’s disease and their caregivers. When depression lingers untreated for weeks while a traditional antidepressant slowly builds to therapeutic levels, cognitive function, motivation, and caregiving capacity all suffer. The newer medications — Auvelity, Spravato, Exxua, and Caplyta among them — represent fundamentally different pharmacological approaches that target glutamate signaling, serotonin 5-HT1A receptors, and other mechanisms that were essentially untouched by older drugs. This article examines each of these recently approved treatments in detail, including how they work, what the clinical trial data actually show, their limitations and costs, and what they may mean for people dealing with depression in the context of brain health and aging. We will also look at a newly cleared non-drug device option and discuss practical considerations for patients and families weighing these choices with their physicians.
Table of Contents
- What New Fast-Acting Antidepressants Have Been Approved for Major Depressive Disorder?
- How Do These New Antidepressants Differ from Traditional SSRIs and SNRIs?
- Caplyta and the Role of Adjunctive Therapy in Treating Depression
- Comparing Costs, Access, and Practical Tradeoffs of New Antidepressants
- Safety Concerns and Limitations Older Adults Should Know About
- Non-Drug Options — The First At-Home Brain Stimulation Device for Depression
- What the Future Holds for Depression Treatment and Brain Health
- Conclusion
- Frequently Asked Questions
What New Fast-Acting Antidepressants Have Been Approved for Major Depressive Disorder?
The most significant recent approval in terms of speed of onset is Auvelity (dextromethorphan/bupropion), manufactured by Axsome Therapeutics. Approved on August 19, 2022, it is the first and only oral rapid-acting antidepressant with FDA labeling that documents statistically significant symptom improvement versus placebo beginning at one week. The medication combines 45 mg of dextromethorphan with 105 mg of bupropion, taken twice daily. Unlike every oral antidepressant that preceded it, Auvelity does not primarily target the monoamine neurotransmitters — serotonin, dopamine, and norepinephrine — that have been the basis of antidepressant pharmacology since the 1950s. Instead, it acts on NMDA and sigma-1 receptors, modulating the glutamate system, which plays a central role in neural plasticity and mood regulation. The clinical evidence behind Auvelity comes from two pivotal trials. The GEMINI trial enrolled 327 patients and found that those taking Auvelity experienced a 16-point drop on the Montgomery-Åsberg Depression Rating Scale (MADRS) at six weeks, compared with a 12-point drop for placebo.
Roughly 40 percent of patients on Auvelity achieved remission, versus 17 percent on placebo. The smaller ASCEND trial, with 97 patients, compared Auvelity directly against bupropion alone and found a MADRS reduction of 14 points versus 9 points, with remission rates of 47 percent versus 16 percent. Perhaps most encouraging, long-term open-label extension data showed remission rates approaching 70 percent and response rates exceeding 80 percent at 12 to 15 months of treatment. Beyond Auvelity, January 2025 brought an important expansion for Spravato (esketamine), manufactured by Janssen, a Johnson & Johnson company. Originally approved in March 2019 as an add-on to oral antidepressants for treatment-resistant depression, Spravato received a new approval on January 21, 2025, as the first and only standalone monotherapy for adults with treatment-resistant depression — defined as inadequate response to at least two oral antidepressants. This is a different patient population than Auvelity targets, but the speed is notable: the TRD4005 trial demonstrated rapid improvement in depressive symptoms versus placebo as early as 24 hours after administration. At week four, 22.5 percent of patients on esketamine achieved remission compared to 7.6 percent on placebo. However, Spravato is an intranasal spray administered at 56 mg or 84 mg doses twice weekly and must be given at certified treatment centers under medical supervision through a Risk Evaluation and Mitigation Strategy (REMS) program, which limits accessibility.
How Do These New Antidepressants Differ from Traditional SSRIs and SNRIs?
The most important distinction is mechanistic. For three decades, nearly every antidepressant on the market worked by increasing the availability of serotonin, norepinephrine, or dopamine in the synaptic cleft. The newer approvals break from this model entirely. Auvelity modulates glutamate through NMDA receptor antagonism and sigma-1 receptor activity. Spravato works as a non-selective, non-competitive NMDA receptor antagonist, also targeting the glutamate system. Exxua (gepirone ER), approved on September 28, 2023, takes yet another novel path as the first and only oral selective serotonin 5-HT1A receptor agonist approved for MDD — a mechanism distinct from SSRIs, which block serotonin reuptake rather than directly stimulating the receptor. This diversity of mechanisms matters clinically because it means patients who do not respond to one pathway now have genuinely different pharmacological options rather than variations on the same theme. The practical differences extend to side effect profiles, which is particularly relevant for older adults and people with cognitive concerns. Exxua’s FDA label carries no warnings for sexual dysfunction or weight gain, two of the most common reasons patients discontinue SSRIs and SNRIs.
Its most common adverse events at 5 percent incidence or higher — dizziness, nausea, insomnia, abdominal pain, and dyspepsia — tend to be mild, short in duration, and related to dose escalation. For an older adult already dealing with metabolic concerns or taking medications that affect weight, this profile represents a meaningful advantage. Exxua was studied in over 5,000 patients total, with its approval based on two randomized, double-blind, eight-week, placebo-controlled trials enrolling 456 patients, in which gepirone showed significantly greater improvement on the Hamilton Rating Scale for Depression versus placebo. The drug is being commercialized in the United States through an exclusive agreement between Fabre-Kramer Pharmaceuticals and Aytu BioPharma. However, it is important not to overstate the “rapid-acting” label. Auvelity’s one-week separation from placebo, while genuinely faster than traditional antidepressants, does not mean patients feel completely well within days. The remission rates, while impressive at 40 to 47 percent in trials, still mean that more than half of patients did not achieve remission in the acute study period. For Spravato, the 24-hour improvement signal is rapid, but the four-week remission rate of 22.5 percent is modest, and the requirement for twice-weekly supervised clinic visits creates a significant logistical burden — especially for older adults with mobility limitations or those living in rural areas without nearby certified centers. Patients and caregivers should approach these medications with realistic expectations: faster does not mean instant, and better does not mean universally effective.
Caplyta and the Role of Adjunctive Therapy in Treating Depression
Not every patient with major depressive disorder will respond adequately to a single medication, and this is where adjunctive treatments — medications added on top of an existing antidepressant — play a critical role. Caplyta (lumateperone), manufactured by Intra-Cellular Therapies (now part of Johnson & Johnson), received FDA approval on November 6, 2025, as an add-on therapy for adults with MDD who are already taking an antidepressant but not getting sufficient relief. This marked Caplyta’s fourth FDA-approved indication, adding to its earlier approvals in schizophrenia and bipolar depression. The clinical data for Caplyta in MDD come from two Phase III trials. Study 501 enrolled 485 patients, and Study 502 enrolled 480 patients. Both demonstrated significant improvement on the MADRS compared to placebo, with separations of 4.9 and 4.5 points respectively, translating to effect sizes of 0.61 and 0.56 — considered medium to large in psychiatric research.
The long-term picture was even more encouraging: in a 26-week open-label extension, Caplyta produced an 80 percent response rate and a 65 percent remission rate at six months. These numbers suggest that for patients willing to stay on treatment, the benefits continue to accrue well beyond the initial trial period. A notable advantage of Caplyta over some other adjunctive options, such as atypical antipsychotics like aripiprazole or quetiapine, is its relatively favorable metabolic, weight, and movement-related side effect profile. For older adults, drug-induced weight gain and extrapyramidal symptoms (involuntary movements) are serious concerns that can worsen mobility, increase fall risk, and complicate existing health conditions. That said, Caplyta is not without drawbacks: in clinical trials, 12.4 percent of patients discontinued due to adverse events, compared to just 0.8 percent on placebo. This discontinuation rate warrants honest conversation between patient and prescriber about what to expect and when to reassess.
Comparing Costs, Access, and Practical Tradeoffs of New Antidepressants
One of the sharpest contrasts among these new treatments is in cost and accessibility. Auvelity carries a price tag of approximately $1,200 per month, which places it well outside the range of generic SSRIs that cost $4 to $30 per month at most pharmacies. For patients with robust prescription drug coverage, this may be manageable, but for older adults on Medicare Part D or those in the coverage gap, the out-of-pocket expense can be prohibitive. Axsome Therapeutics offers a patient assistance program, but navigating manufacturer copay cards and prior authorization requirements adds friction to an already difficult time. Spravato, as a clinic-administered intranasal treatment, involves not only medication costs but also the expense of twice-weekly facility visits, provider supervision fees, and the two-hour monitoring period required after each dose. Exxua and Caplyta, while also branded medications without generic equivalents, are oral pills taken at home, which reduces the logistical burden compared to Spravato. The tradeoff is that oral medications require consistent daily adherence, while Spravato’s supervised model at least guarantees that doses are administered correctly.
For a caregiver managing medications for a loved one with depression and early dementia, the simplicity of a once- or twice-daily pill may outweigh the theoretical advantage of supervised dosing. Conversely, for a patient with treatment-resistant depression who has failed multiple oral medications, the controlled setting of Spravato administration may provide both clinical benefit and a structured touchpoint with a healthcare team. When choosing among these options, the decision should account for the specific clinical scenario. A patient with a first episode of moderate MDD who wants to avoid sexual side effects might be well served by Exxua. Someone who needs faster onset and can afford the cost might consider Auvelity. A patient with documented treatment-resistant depression who has failed two or more oral antidepressants now has Spravato available as monotherapy rather than as an add-on. And for those already on an antidepressant with partial response, Caplyta offers an adjunctive option with a strong six-month remission profile. None of these decisions should be made in isolation — they require candid discussion with a prescriber who knows the patient’s full medical history, cognitive status, and financial situation.
Safety Concerns and Limitations Older Adults Should Know About
While the newer antidepressants offer genuine advances, they are not without risks that deserve particular attention in the context of aging and brain health. Spravato’s most common adverse events — dissociation, nausea, dizziness, headache, sedation, and increased blood pressure — are especially concerning for older adults. Dissociative experiences can be disorienting and frightening for someone already experiencing cognitive changes, and transient blood pressure elevations may be dangerous for patients with cardiovascular disease or those taking antihypertensives. The REMS program requirement exists precisely because of these safety concerns; patients must be monitored in a certified healthcare facility for at least two hours after each dose. Auvelity contains dextromethorphan, which is metabolized by the CYP2D6 enzyme system and has interactions with a wide range of medications, including MAO inhibitors and other serotonergic drugs. The bupropion component lowers the seizure threshold, which is a relevant consideration for patients with a history of seizures or those taking other medications that increase seizure risk.
Older adults tend to be on more medications simultaneously, raising the likelihood of clinically significant drug interactions. Any prescriber considering Auvelity for an older patient must conduct a thorough medication reconciliation. It is also worth noting that none of these newer medications have been specifically studied in populations with dementia. The clinical trials enrolled adults with major depressive disorder but generally excluded patients with significant cognitive impairment or neurodegenerative disease. This does not mean the drugs cannot be used in such patients, but it does mean that efficacy and safety data are being extrapolated rather than directly demonstrated. Clinicians treating depression in a patient with comorbid dementia are working with less evidence than the headline trial results suggest, and close monitoring is essential.
Non-Drug Options — The First At-Home Brain Stimulation Device for Depression
In December 2025, the FDA approved the first at-home, non-drug brain stimulation device for moderate-to-severe major depressive disorder, developed by Flow Neuroscience. The device can be used either as a standalone treatment or in combination with antidepressant medication, giving patients and clinicians another tool in a growing arsenal. For individuals who cannot tolerate medication side effects, who prefer non-pharmacological approaches, or who want to augment their current treatment, this represents a genuinely new category of accessible intervention.
The at-home aspect is particularly relevant for older adults and caregivers. Traditional brain stimulation therapies like transcranial magnetic stimulation (TMS) or electroconvulsive therapy (ECT) require repeated clinic visits and, in the case of ECT, general anesthesia. A device that can be used safely at home removes transportation barriers and fits more easily into the daily routine of someone managing chronic illness or caregiving responsibilities. However, patients should discuss this option with their physician before use, as brain stimulation is not appropriate for everyone and should be part of a coordinated treatment plan.
What the Future Holds for Depression Treatment and Brain Health
The pace of antidepressant innovation over the past few years has been unlike anything the field has seen since the introduction of Prozac in 1988. With four mechanistically novel medications approved between 2022 and 2025, plus a new device-based option, the treatment paradigm for depression is becoming more personalized. Researchers are increasingly studying how depression interacts with neurodegeneration, and there is growing interest in whether glutamate-targeting medications like Auvelity or Spravato might have neuroprotective effects beyond their antidepressant activity. These are preliminary questions without definitive answers, but they reflect a shift toward understanding depression not just as a mood disorder but as a condition with direct implications for brain structure and function over time.
For families affected by dementia, this evolution in depression treatment carries a particular urgency. Untreated or undertreated depression accelerates cognitive decline, undermines rehabilitation efforts, and erodes caregiver well-being. Every month spent waiting for a traditional antidepressant to reach full effect is a month of unnecessary suffering with potential long-term consequences. While no medication is a cure-all, having faster-acting and better-tolerated options gives clinicians more flexibility to match treatment to the patient rather than forcing patients to endure a one-size-fits-all approach. The next several years will likely bring further refinements, including better biomarkers for predicting which patients respond to which mechanism, and possibly new indications for these medications in populations with comorbid cognitive impairment.
Conclusion
The approval of Auvelity, the expansion of Spravato to monotherapy, and the introduction of Exxua and Caplyta collectively represent the most significant diversification of antidepressant options in a generation. Each targets a different mechanism, offers a distinct clinical profile, and addresses different gaps in existing treatment. For older adults and dementia caregivers dealing with depression, the availability of faster-acting medications with potentially more tolerable side effect profiles is a meaningful step forward — though cost, access, and the absence of dementia-specific trial data remain real limitations.
The practical takeaway is that patients and caregivers should not assume their only options are the same SSRIs that have been available for decades. A conversation with a knowledgeable prescriber about these newer medications — what they offer, what they cost, and whether they are appropriate given the full clinical picture — is a reasonable and worthwhile step. Depression in the context of aging and cognitive decline deserves aggressive, thoughtful treatment, and the tools to provide that treatment are better now than they have ever been.
Frequently Asked Questions
How fast does Auvelity work compared to traditional antidepressants?
Auvelity’s FDA labeling shows statistically significant improvement versus placebo starting at one week. Traditional SSRIs and SNRIs typically require four to six weeks to reach full therapeutic effect, though some patients notice partial improvement sooner. In the GEMINI trial, Auvelity produced a 16-point MADRS score reduction at six weeks with approximately 40 percent of patients achieving remission.
Can Spravato now be used without another antidepressant?
Yes. As of January 21, 2025, Spravato (esketamine) is approved as a standalone monotherapy for adults with treatment-resistant depression who have not responded adequately to at least two oral antidepressants. Previously, it could only be prescribed as an add-on to an oral antidepressant. It must still be administered at a certified treatment center under supervision.
Are any of these new antidepressants specifically tested in people with dementia?
No. The clinical trials for Auvelity, Spravato, Exxua, and Caplyta enrolled adults with major depressive disorder but generally excluded patients with significant cognitive impairment or neurodegenerative disease. Clinicians may still prescribe them off-label for patients with comorbid depression and dementia, but this involves clinical judgment rather than direct trial evidence.
Which new antidepressant has the fewest sexual side effects?
Exxua (gepirone ER) is notable for carrying no FDA label warnings for sexual dysfunction or weight gain, which distinguishes it from SSRIs and SNRIs where these side effects are common. Its most frequent side effects — dizziness, nausea, and insomnia — tend to be mild and related to dose escalation.
What does Caplyta add when used alongside an existing antidepressant?
In Phase III trials, adding Caplyta to an existing antidepressant produced MADRS improvements of 4.9 and 4.5 points over placebo, with effect sizes of 0.61 and 0.56. Over six months in open-label extension, 80 percent of patients responded and 65 percent achieved remission. It has a relatively favorable profile regarding weight gain and movement-related side effects compared to some other adjunctive options.
Is the at-home brain stimulation device a replacement for medication?
The Flow Neuroscience device, approved by the FDA in December 2025, can be used either as a standalone treatment or in combination with antidepressant medication for moderate-to-severe MDD. It is not positioned as a universal replacement for medication but rather as an additional option, particularly for patients who cannot tolerate drugs or who want a non-pharmacological approach. It should be used under physician guidance.
